EGFR Exon 20 Insertion As A Therapeutic Target in Non-small Cell Lung Cancer

Zofia Piotrowska, MD, provides an overview of EGFR mutations in advanced NSCLC, including EGFR Exon 20 insertions, and their clinical significance in patients with advanced NSCLC.

Zofia Piotrowska, MD, shares insight on testing strategies for EGFR Exon 20 insertions, and which patients should be tested for these alterations.

Zofia Piotrowska, MD, reviews historical treatment approaches for patients with NSCLC and EGFR exon 20 insertions.

Zofia Piotrowska, MD, discusses the role of amivantamab in the treatment of patients with NSCLC and EGFR exon 20 insertions.

Zofia Piotrowska, MD, evaluates the use of mobocertinib in patients with NSCLC and EGFR exon 20 insertions and provides updated results from key trials of mobocertinib in EGFR exon 20-positive NSCLC.

Zofia Piotrowska, MD, shares insights on factors to consider when selecting the appropriate therapy for patients with EGFR exon 20-positive NSCLC.

Zofia Piotrowska, MD, discusses unmet needs, novel treatment strategies and future perspectives for patients with EGFR exon 20-positive NSCLC.

Zofia Piotrowska, MD, discusses potential therapies for patients with EGFR exon 20 insertion-positive non–small cell lung cancer.

In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.